(Boursier.com) — Icade holds its 2022 investor day. The opportunity for the group to highlight its resilience and its ability to adapt to the new environment, and to revise upwards its current net cash flow estimates for 2022. The 2022 group NCCF per 2022 share is expected to rise by 7% excluding the effect of 2022 disposals, against +4% previously estimated. This represents an increase of 3% with the effect of the 2022 disposals, estimated at 14 million euros. The 2022 CFNC for Health Property Investment is expected to increase by 5.7-6% in value. The group confirms the 2022 dividend policy with an expected increase of 3-4%, subject to validation by the 2023 AGM.
For 2023, Icade claims to have “very solid” fundamentals, with a solid financial structure, an office portfolio with real advantages in its market, healthcare assets with confirmed attractiveness (“investment ambition of 3 billion euros to be adapted, liquidity still on the roadmap”), a development activity which should continue its dynamic of growth and improved profitability, and a low-carbon ambition to serve the attractiveness of the three business lines. Icade will announce a new medium-term plan on February 20 when the annual results are published.
©2022 Boursier.com
